ARDS vs. CALA, SCPS, CMRA, GNCAQ, GNCA, SMFL, STAB, AMPE, CLVR, and ONCSQ
Should you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Calithera Biosciences (CALA), Scopus BioPharma (SCPS), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Smart for Life (SMFL), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Clever Leaves (CLVR), and OncoSec Medical (ONCSQ). These companies are all part of the "pharmaceutical products" industry.
Aridis Pharmaceuticals vs. Its Competitors
Aridis Pharmaceuticals (NASDAQ:ARDS) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.
In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.
Calithera Biosciences received 219 more outperform votes than Aridis Pharmaceuticals when rated by MarketBeat users. However, 61.00% of users gave Aridis Pharmaceuticals an outperform vote while only 55.09% of users gave Calithera Biosciences an outperform vote.
9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Aridis Pharmaceuticals has higher revenue and earnings than Calithera Biosciences.
Aridis Pharmaceuticals has a beta of 12.09, meaning that its share price is 1,109% more volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of -2.56, meaning that its share price is 356% less volatile than the S&P 500.
Summary
Aridis Pharmaceuticals beats Calithera Biosciences on 5 of the 7 factors compared between the two stocks.
Get Aridis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Aridis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ARDS) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy ARDS Stock Free ARDS Stock Alerts